NEO

#1894
NeoGenomics, Inc. - Common Stock
10.5 2 USD
+3.14%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
10.52
10.52
Range Annuel
4.72
13.74
Changement quotidien
+3.14%
Changement Mensuel
+16.11%
Evolution sur 6 mois
-12.33%
Changement Annuel
+42.93%
Clôture Précédente
10.2 0
Open
10.5 2
Low
10.5 2
High
10.5 2
Volume
154
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 1.37 B
  • Employee 2 500
  • Founded 2002
  • CEO Christopher M. Smith
  • Website www.neogenomics.com
  • Headquarter Nevada, United States
  • FIGI BBG000BKH263
  • Industry Diagnostic et Recherche
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-13.95
ratio cours/chiffre d'affaires
2.07

NeoGenomics, Inc. - Common Stock

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas.

Nouvelles